These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 35032297)

  • 21. Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors.
    DeRenzo C; Gottschalk S
    Front Immunol; 2019; 10():218. PubMed ID: 30828333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CAR-T Cell Therapy: Challenges and Optimization.
    Luo M; Zhang H; Zhu L; Xu Q; Gao Q
    Crit Rev Immunol; 2021; 41(1):77-87. PubMed ID: 33822526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
    Chen J; Jiang H
    Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
    Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
    Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
    Mao R; Hussein MS; He Y
    Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in CAR-T cell therapy for malignant solid tumors.
    Liu J; Tu X; Liu L; Fang W
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):175-184. PubMed ID: 36161290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future.
    Zhang Z; Miao L; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():718686. PubMed ID: 34386015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells in Humans.
    Liu C; Ayyar VS; Zheng X; Chen W; Zheng S; Mody H; Wang W; Heald D; Singh AP; Cao Y
    Clin Pharmacol Ther; 2021 Mar; 109(3):716-727. PubMed ID: 33002189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering chimeric antigen receptor-T cells for cancer treatment.
    Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
    Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR T cells in solid tumors: challenges and opportunities.
    Marofi F; Motavalli R; Safonov VA; Thangavelu L; Yumashev AV; Alexander M; Shomali N; Chartrand MS; Pathak Y; Jarahian M; Izadi S; Hassanzadeh A; Shirafkan N; Tahmasebi S; Khiavi FM
    Stem Cell Res Ther; 2021 Jan; 12(1):81. PubMed ID: 33494834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death.
    Wang Y; Zhang H; Du G; Luo H; Su J; Sun Y; Zhou M; Shi B; Li HQX; Jiang H; Li Z
    Mol Ther; 2023 Mar; 31(3):701-714. PubMed ID: 36523165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.
    Hashem Boroojerdi M; Rahbarizadeh F; Safarzadeh Kozani P; Kamali E; Safarzadeh Kozani P
    Med Oncol; 2020 Oct; 37(11):100. PubMed ID: 33047234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene modification strategies for next-generation CAR T cells against solid cancers.
    Tian Y; Li Y; Shao Y; Zhang Y
    J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.